Novavax (NVAX) Q3 2026 Earnings
Quarter includes $11 million in non-cash deferred royalty recognition related to prior Nuvaxovid sales by SK bioscience to the South Korean government; no non-GAAP EPS disclosed.
How Did NVAX Stock React to Q3 2026 Earnings?
Did NVAX Beat Earnings? Q3 2026 Results
Yes. Novavax reported Q3 2026 earnings of $-0.19 a share on Nov 5, 2026, beating the $-0.35 consensus estimate by 45.1%. Revenue was $68.3M against a $50.4M estimate.
Novavax delivered a decisive beat in the third quarter of 2026, posting GAAP EPS of negative $0.19 against a consensus estimate of negative $0.35, a 45.09% positive surprise, while revenue of $68.30 million cleared the $50.42 million consensus by 35.45%, even as the top line slipped 3.0% year over year. The quarter's results, which included $11.00 million in non-cash deferred royalty recognition tied to SK bioscience's prior Nuvaxovid sales to the South Korean government, reflected Novavax's continuing pivot toward a partnership- and royalty-driven model; product sales surged 91% to roughly $26.00 million on Nuvaxovid supply to Sanofi, partly offsetting a sharp drop in R&D reimbursement revenue as Novavax winds down its clinical support for Sanofi's postmarketing commitments. Sanofi's October initiation of a Phase 3 European trial for a combination influenza-COVID-19 vaccine, which triggered a $125.00 million milestone for Novavax, prompted management to raise full-year 2026 Non-GAAP Adjusted Total Revenue guidance to $385.00 million to $415.00 million, up from a prior range of $235.00 million to $275.00 million.
- Product sales up 91% on supply sales of Nuvaxovid to Sanofi and Matrix-M to license partners
- Licensing revenue down 25%, driven by a $42 million year-over-year reduction in R&D reimbursement revenue
- $11 million non-cash deferred royalty recognition related to SK bioscience prior Nuvaxovid sales
- R&D expenses down 47% on near completion of Sanofi clinical support, reduced strain change support and cost reduction
- SG&A down 25% on transition of commercial activities to Sanofi and elimination of commercial infrastructure
- No repeat of the prior-year $97.0 million impairment and $28.7 million loss on debt extinguishment
“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment.”
Novavax CEO, on the earnings call
What Is Novavax's Outlook?
Novavax raised its full-year 2026 Non-GAAP Adjusted Total Revenue framework to $385–$415 million, from $235–$275 million as of August 6, 2026. The framework's components are: - Nuvaxovid Product Sales of $40–$50 million, expected to be excluded from the 2027 framework. - Adjusted Supply Sales of $50–$60 million. - The $125 million Sanofi CIC milestone. - Adjusted Licensing, Royalties and Other Revenue of $170–$180 million, made up of: - $60 million in R&D reimbursement, with $5 million expected in 2027. - $70–$80 million of other partner revenue, including the $30 million Pfizer upfront payment. - $40 million of amortization of the Sanofi upfront and database lock payments. Full-year 2026 expense guidance: - Combined R&D and SG&A Expenses of $375–$395 million, versus $370–$410 million previously. - Non-GAAP Combined R&D and SG&A Expenses of $315–$335 million, versus $310–$340 million previously. Sanofi supply sales, royalties and future milestones are excluded from guidance. Expected Sanofi milestones include: - $75 million on completion of the technology transfer, expected mid-2027. - $225 million on the first U.S. commercial sale of a CIC vaccine. Sanofi intends to start a U.S. Phase 3 CIC trial in 2027.
NVAX YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $68.3M | $70.4M | −3.1% |
| Operating Income | −$31.3M | −$17.1M | +82.4% |
| Net Income | −$31.4M | −$17.0M | +84.5% |
NVAX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.